The effect of octreotide on urine output during orthotopic liver transplantation and early postoperative renal function; a randomized, double-blind, placebo-controlled trial

Mohammad Ali Sahmeddini, Afshin Amini, Nima Naderi, Mohammad Ali Sahmeddini, Afshin Amini, Nima Naderi

Abstract

Background: Maintenance of the adequate intraoperative renal perfusion is very important during Orthotopic Liver Transplantation (OLT) to prevent acute renal failure.

Objectives: For the first time, this study was designed to survey the effects of octreotide on urine output during anesthesia for OLT and early postoperative renal function.

Patients and methods: In this randomized double-blind placebo controlled clinical trial, 79 of 89 patients who underwent OLT and fulfilled the study requirement were randomly allocated into two groups. In the octreotide group, the patients received octreotide infusion from the start of the operation. On the other hand, the control group patients received physiologic saline infusion instead of octreotide. The Mean Arterial Pressure (MAP), heart rate, urine output, norepinephrine usage, and dosage during the three stages of OLT, and baseline and postoperative creatinine were recorded and compared between the two groups.

Results: No significant differences were found between the two groups regarding the demographic characteristics and graft factors (P > 0.05). However, urine output and MAP during the three stages of OLT were significantly higher in the octreotide group compared to the control group (P < 0.05). Moreover, no significant difference was observed between the two groups regarding baseline as well as postoperative creatinine (P > 0.05).

Conclusions: The results demonstrated that octreotide infusion during anesthesia for OLT not only augmented the vasoconstriction effect of norepinephrine to increase MAP, but also maintained better renal perfusion and urine output during the operation.

Keywords: Acute Kidney Injury; Liver Transplantation; Octreotide.

Figures

Figure 1.. Flowchart of the Patients According…
Figure 1.. Flowchart of the Patients According to the Consort Guidelines

References

    1. Junge G, Schewior LV, Kohler S, Neuhaus R, Langrehr JM, Tullius S, et al. Acute renal failure after liver transplantation: incidence, etiology, therapy, and outcome. Transplant Proc. 2006;38(3):723–4. doi: 10.1016/j.transproceed.2006.01.074.
    1. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant. 2007;7(1):168–76. doi: 10.1111/j.1600-6143.2006.01602.x.
    1. Steadman RH, Csete M. Complications of liver transplantation. Seminars in Anesthesia, Perioperative Medicine and Pain. 1996;15(3):250–5. doi: 10.1016/S0277-0326(96)80015-8.
    1. Lewandowska L, Matuszkiewicz-Rowinska J. Acute kidney injury after procedures of orthotopic liver transplantation. Ann Transplant. 2011;16(2):103–8.
    1. Rueggeberg A, Boehm S, Napieralski F, Mueller AR, Neuhaus P, Falke KJ, et al. Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients. Anaesthesia. 2008;63(11):1174–80. doi: 10.1111/j.1365-2044.2008.05604.x.
    1. Fonseca-Neto OCLD, Miranda LEC, Melo PS, Sabat BD, Amorim AG, Lacerda CM. Predictors of acute kidney injury in patients undergoing a conventional orthotopic liver transplant without veno-venous bypass. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo). 2011;24(2):152–158.
    1. Lima EQ, Zanetta DM, Castro I, Massarollo PC, Mies S, Machado MM, et al. Risk factors for development of acute renal failure after liver transplantation. Ren Fail. 2003;25(4):553–60.
    1. Steadman RH. Anesthesia for liver transplant surgery. Anesthesiol Clin North America. 2004;22(4):687–711. doi: 10.1016/j.atc.2004.06.009.
    1. Mandell MS, Katz JJ, Wachs M, Gill E, Kam I. Circulatory pathophysiology and options in hemodynamic management during adult liver transplantation. Liver Transplantation and Surgery. 1997;3(4):379–387. doi: 10.1002/lt.500030411.
    1. Planinsic RM, Lebowitz JJ. Renal failure in end-stage liver disease and liver transplantation. Int Anesthesiol Clin. 2006;44(3):35–49. doi: 10.1097/01.aia.0000210807.24298.f7.
    1. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007;13(42):5552–9.
    1. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279–90. doi: 10.1056/NEJMra0809139.
    1. Schrier RW, Shchekochikhin D, Ginès P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrol Dial Transpl. 2012;27(7):2625–8.
    1. Arroyo V. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther. 2004;20 Suppl 3:49–54. doi: 10.1111/j.1365-2036.2004.02114.x. discussion 55-6.
    1. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690–7. doi: 10.1002/hep.510290629.
    1. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51(2):576–84. doi: 10.1002/hep.23286.
    1. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008;48 Suppl 1:S93–103. doi: 10.1016/j.jhep.2008.01.010.
    1. Cardenas A, Arroyo V. Renal and circulatory dysfunction in liver cirrhosis. Pathogenesis and treatment. Ann Gastroenterol. 2007;14(3)
    1. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40(1):55–64. doi: 10.1002/hep.20262.
    1. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant. 2005;20(9):1813–20. doi: 10.1093/ndt/gfh930.
    1. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003;38(1):238–43. doi: 10.1053/jhep.2003.50276.
    1. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001;120(4):975–83.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren